| Titolo |
Pubblicato in |
Anno |
| Saxagliptin/dapagliflozin is non‐inferior to insulin glargine in terms of β‐cell function in subjects with latent autoimmune diabetes in adults: A 12‐month, randomized, comparator‐controlled pilot study |
DIABETES, OBESITY AND METABOLISM |
2024 |
| Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk |
THE LANCET REGIONAL HEALTH. EUROPE |
2024 |
| IDegLira for the real-world treatment of type 2 diabetes in Italy. Final results from the REX observational study |
DIABETES, OBESITY AND METABOLISM |
2024 |
| Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes |
EXPERT OPINION ON INVESTIGATIONAL DRUGS |
2024 |
| Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk |
THE LANCET REGIONAL HEALTH. EUROPE |
2024 |
| LADA 30th anniversary: A growing form of diabetes with persistent unresolved questions |
DIABETES/METABOLISM RESEARCH AND REVIEWS |
2024 |
| No differences in kidney function decline between people with type 2 diabetes starting a sodium-glucose cotransporter 2 inhibitor or a glucagon-like peptide-1 receptor agonist: a real-world retrospective comparative observational study |
CLINICAL THERAPEUTICS |
2024 |
| Open questions on basal insulin therapy in T2D: a Delphi consensus |
ACTA DIABETOLOGICA |
2024 |
| Improved HbA1c and body weight in GADA-positive individuals treated with tirzepatide: A post hoc analysis of SURPASS |
THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM |
2024 |
| Correction: An updated algorithm for an effective choice of continuous glucose monitoring for people with insulin-treated diabetes |
ENDOCRINE |
2024 |
| Deterioration of Vestibular Motion Perception: A Risk Factor for Postural Instability and Falls in Elderly With Type 2 Diabetes |
DIABETES/METABOLISM RESEARCH AND REVIEWS |
2024 |
| Type 2 diabetes in children and adolescents: Challenges for treatment and potential solutions |
DIABETES RESEARCH AND CLINICAL PRACTICE |
2024 |
| Association of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes |
DIABETES/METABOLISM RESEARCH AND REVIEWS |
2023 |
| Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: A systematic review and meta-analysis of randomized controlled trials |
DIABETES, OBESITY AND METABOLISM |
2023 |
| Sex Differences in Cardiovascular Disease and Cardiovascular Risk Estimation in Patients With Type 1 Diabetes |
THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM |
2023 |
| Short-term effectiveness of dapagliflozin versus {DPP}-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study |
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION |
2023 |
| Lack of Association between Serum Chitotriosidase Activity and Arterial Stiffness in Type 2 Diabetes without Cardiovascular Complications |
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
2023 |
| Glycated haemoglobin in the first year after diagnosis of type 1 diabetes is an independent risk factor for diabetic retinopathy: The IMDIAB 25 years follow-up study |
DIABETES, OBESITY AND METABOLISM |
2023 |
| Validation in type 2 diabetes of a metabolomic signature of all-cause mortality |
DIABETES/METABOLISM RESEARCH AND REVIEWS |
2023 |
| Association of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes |
DIABETES/METABOLISM RESEARCH AND REVIEWS |
2023 |
